Trials / Active Not Recruiting
Active Not RecruitingNCT05797740
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 367 (actual)
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to describe participants characteristics that can predict the safety and effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with cladribine tablets, and to assess other patient-reported, clinical, and imaging outcomes in participants with relapsing multiple sclerosis (RMS) in the long term, in a real-world setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mavenclad | This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included. |
Timeline
- Start date
- 2023-08-03
- Primary completion
- 2029-01-31
- Completion
- 2029-01-31
- First posted
- 2023-04-04
- Last updated
- 2026-02-19
Locations
30 sites across 6 countries: Belgium, Czechia, Greece, Netherlands, Poland, Portugal
Source: ClinicalTrials.gov record NCT05797740. Inclusion in this directory is not an endorsement.